Ultragenyx Pharmaceutical Inc Finding a Needle in a Haystack - Drug Development Strategies for Rare Disease Panel at Citi BioPharma Conference (Virtual) Transcript
Welcome, everyone, to the session, Finding a Needle in a Haystack, Drug Development Strategies for Rare Disease. I'm Yigal Nochomovitz one of the biotech analysts here at Citi. And it's my pleasure to have with me this afternoon 4 distinguished panelists from Dicerna Pharmaceuticals, Douglas Fambrough, the CEO; from Eiger BioPharmaceuticals, David Cory, President and CEO; from ProQR Therapeutics, Smital Shah, who is the CFO and CBO; and from Ultragenyx Pharmaceutical, Emil Kakkis, President and CEO. So welcome all of you. Thank you very, very much for participating in the panel.
And maybe just to start things off, if each of you could provide a very brief 2 to 3-minute introduction to the company, what does your pipeline look like, what are the key clinical and commercial catalysts that are coming up for each of you. Maybe we could start with Emil.
Sure. Thanks for having us, Yigal.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |